Back to top

oncology-screening: Archive

Zacks Equity Research

Teva Partners With Fosun to Develop TEV-56278 Immuno-Cancer Therapy

TEVA teams up with Fosun to speed the development of TEV-56278, a novel anti-cancer immunotherapy targeting PD-1+ T cells.

TEVANegative Net Change BAYRYPositive Net Change AGENNegative Net Change IMCRPositive Net Change

Zacks Equity Research

JNJ's Combo Therapy Shows Strong Phase III Efficacy in Prostate Cancer

Johnson & Johnson's niraparib combo significantly delays prostate cancer progression in HRR-altered patients with strong phase III data.

JNJPositive Net Change BAYRYPositive Net Change LXRXNo Net Change AMRNPositive Net Change

Zacks Equity Research

ORIC Stock Surges on Upbeat Initial Data From Prostate Cancer Study

ORIC Pharmaceuticals stock rises 20% pre-market on early data showing strong PSA responses and tolerability for prostate cancer drug ORIC-944 in phase Ib study.

JNJPositive Net Change BAYRYPositive Net Change AMRNPositive Net Change ORICPositive Net Change

Zacks Equity Research

BMY's Opdivo SC Gets EU Nod for Multiple Solid Tumor Indications

Bristol Myers' Opdivo SC wins EU approval as the first PD-1 inhibitor for subcutaneous use across multiple solid tumor indications.

BMYPositive Net Change BAYRYPositive Net Change LXRXNo Net Change AMRNPositive Net Change